CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade X4 Pharmaceuticals, Inc. - XFOR CFD

0.97
3%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1
Open 0.98
1-Year Change -53.33%
Day's Range 0.94 - 1
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 14, 2024 1.00 -0.01 -0.99% 1.01 1.01 0.95
Jun 13, 2024 1.04 -0.03 -2.80% 1.07 1.10 1.00
Jun 12, 2024 1.08 0.04 3.85% 1.04 1.10 1.04
Jun 11, 2024 1.02 0.02 2.00% 1.00 1.04 0.99
Jun 10, 2024 1.02 0.03 3.03% 0.99 1.04 0.98
Jun 7, 2024 0.98 0.00 0.00% 0.98 1.01 0.94
Jun 6, 2024 1.00 -0.02 -1.96% 1.02 1.04 0.98
Jun 5, 2024 1.05 0.02 1.94% 1.03 1.07 0.99
Jun 4, 2024 1.05 0.09 9.38% 0.96 1.06 0.95
Jun 3, 2024 0.98 0.01 1.03% 0.97 1.00 0.96
May 31, 2024 0.99 0.04 4.21% 0.95 1.01 0.95
May 30, 2024 0.95 0.05 5.56% 0.90 0.98 0.90
May 29, 2024 0.91 0.01 1.11% 0.90 0.94 0.88
May 28, 2024 0.92 0.03 3.37% 0.89 0.95 0.89
May 24, 2024 0.88 0.02 2.33% 0.86 0.91 0.84
May 23, 2024 0.87 -0.03 -3.33% 0.90 0.90 0.84
May 22, 2024 0.88 0.03 3.53% 0.85 0.92 0.85
May 21, 2024 0.87 -0.01 -1.14% 0.88 0.88 0.84
May 20, 2024 0.87 -0.01 -1.14% 0.88 0.89 0.85
May 17, 2024 0.90 -0.02 -2.17% 0.92 0.93 0.87

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

X4 Pharmaceuticals, Inc. Company profile

About X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of therapeutics for the treatment of rare diseases with an initial focus on the treatment of people with immune system dysfunction. Its lead product candidate, mavorixafor, is a small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Its mavorixafor demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells (WBCs), which provides therapeutic benefit across a variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Its mavorixafor is in a global Phase III clinical trial for the treatment of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome, a rare, inherited PID caused by genetic mutations in the CXCR4 receptor gene. Its product candidates include X4P-001, X4P-002 and X4P-003.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, X4 Pharmaceuticals Inc revenues decreased from $3M to $0K. Net loss applicable to common stockholders increased 65% to $102.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 21% to $47.9M (expense).

Industry: Biotechnology & Medical Research (NEC)

61 North Beacon Street
4th Floor
BOSTON
MASSACHUSETTS 02134
US

News

RBA Meeting Preview: No change to policy expected, markets look for fresh guidance

The Reserve Bank of Australia is expected to keep interest rates unchanged at 4.35% when it meets on Tuesday, June 18th, 2024, at 2:30 PM (AEST).

13:17, 17 June 2024

FOMC Decision Review: Rates unchanged as central bank raises inflation and interest rate forecasts

The FOMC left Federal Funds Rate unchanged at a target range of 5.25 to 5.50%.

10:55, 17 June 2024

Bank of Japan Preview: Markets look for guidance from BOJ about timing of next hike

The Bank of Japan meets on Friday, 14th of June, 2024. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

11:05, 12 June 2024

FOMC preview: Still expecting three rate cuts in 2024?

The Federal Reserve is expected to keep its policy unchanged on Wednesday – data from Reuters shows a 99% chance of no change. Last week’s 25-basis-point rate cut from the ECB has done nothing to change market expectations, and why should it?

08:20, 11 June 2024

US Non-Farm Payrolls Preview: Forecasts point to a stable labour market

US labour market conditions are expected to have remained stable in May. The latest Non-Farm Payrolls data will be released on Friday, June 7th, 2024, and will provide a health check on the US jobs market.

10:09, 5 June 2024

AUD/USD analysis: Focus turns to GDP data after unexpected CPI rise

Higher-than-expected monthly CPI data watered down expectations for RBA interest rate cuts in 2024; the markets will now shift attention to quarterly GDP data on Wednesday, June 5.

15:57, 4 June 2024

ECB preview: A cut, but how many more?

After months of waiting, a rate cut from the ECB on Thursday looks like a done deal. Data from Reuters shows markets pricing in a 96% chance of a 25-basis point cut from the European Central Bank following Thursday’s policy meeting.

08:54, 4 June 2024

People also watch

Gold

2,320.14 Price
-0.550% 1D Chg, %
Long position overnight fee -0.0190%
Short position overnight fee 0.0107%
Overnight fee time 21:00 (UTC)
Spread 0.40

ETH/USD

3,515.35 Price
-1.710% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

XRP/USD

0.52 Price
+6.040% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

19,879.50 Price
+1.050% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 620,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading